Welcome to the e-CCO Library!

P515: Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternative
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hammoudi, N.(1)*;Hassid, D.(1);Bonnet, J.(1);Tran Minh, M.L.(1);Baudry, C.(1);Chedouba, L.(1);Vauthier, A.(1);Gornet, J.M.(1);Allez, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P515: Manipulating the microbiome in paediatric acute severe colitis with a cocktail of antibiotics: A pilot randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Turner1*, H. Vlamakis2, D. Marcus1, M. Yassour2, J. Bishai2, B. Yerushalmi3, A. Griffiths4, M. Aloi5, L. Albenberg6, K.-L. Kolho7, G. Abutbul1, A. Assa8, R. Xavier2, A. Levine9

Created: Thursday, 21 February 2019, 9:14 AM
P516 Daily consumers of drip-filtered coffee have a decreased risk of developing late-onset Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Widbom1, J. Hultdin1, K. Ekblom2, P. Karling3, L.M. Nilsson4

Created: Thursday, 30 January 2020, 10:12 AM
P516: Adrenal suppression in inflammatory bowel disease patients treated with glucocorticoids: a systematic review
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wood P.*1, Henderson P.1,2, Wilson D.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P516: Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study
Year: 2022
Source: ECCO'22
Authors: Karki, C.(1);Athavale, A.(2);Hantsbarger, G.(3);Lee, K.(4);Milicevic, S.(5);Perovic, M.(6);Raven, L.(7);Sajak-Szczerba, M.(8);Abilash, V.(2);Tozer, P.(9);
Created: Friday, 11 February 2022, 3:56 PM
P516: Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Panés1*, B. Bressler2, J.-F. Colombel3, N. Lawendy4, E. Maller4, H. Zhang4, D.A. Woodworth4, G. Chan4, L. Salese4, C. Su4

Created: Thursday, 21 February 2019, 9:14 AM
P516: Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Caldera, F.(1)*;Maddux, R.(2);Ungaro, R.(3);Kaur, A.(2);Brown, E.(2);Hu, S.(2);Sheffield, J.K.(2);Silva, D.(2);Harris, S.(2);Cree, B.A.C.(4);
Created: Friday, 14 July 2023, 11:05 AM
P516: Serological biomarkers of tissue remodeling are associated with endoscopic remission in Crohn’s disease patients treated with GED-0301 (mongersen)
Year: 2021
Source: ECCO'21 Virtual
Authors: Mortensen, J.(1);Feagan, B.(2);Bay-Jensen, A.C.(1);Karsdal, M.A.(1);Horan, G.(3);Harris, S.(4);Usikin, K.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P516: The use of first-line biologics in patients with ulcerative colitis in Norway from 2011 to 2016
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Anisdahl*1,2, S. Lirhus3, A. Medhus1, L. Buer1,2, H. O. Melberg3, B. Moum1,2, M. Lie Høivik1

Created: Friday, 22 February 2019, 9:41 AM
P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Hill1,2, J. Popov1,3, E. Hartung1, M. Moshkovich1,4, M. Figueiredo1,4, N. Pai1,5, McMaster Paediatric FMT Research Program

Created: Thursday, 30 January 2020, 10:12 AM
P517: Activity assessment in ulcerative colitis: correlation analysis of endoscopic and histological scores
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Di Ruscio*1, A. Variola1, A. Geccherle1, S. Orlandi1, G. Lunardi2, P. Castelli3, G. Zamboni3, R. Riddell4

Created: Friday, 22 February 2019, 9:41 AM
P517: Features of cytomegalovirus infection in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Makarchuk P., Belousova E., Volchkova E., Kudriavtseva E.

Created: Wednesday, 20 February 2019, 10:36 AM
P517: One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy.
Year: 2021
Source: ECCO'21 Virtual
Authors: Chiappetta, M.F.(1);Viola, A.(1);Mastronardi, M.(2);Turchini, L.(3);Carparellli , S.(4);Orlando, A.(5);Biscaglia , G.(4);Miranda , A.(6);Guida, L.(7);Costantino, G.(1);Scaldaferri, F.(8);Bossa, F.(4);Renna, S.(5);Cappello , M.(7);Orlando , A.(5);Armuzzi, A.(3);Fries, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P517: Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
Year: 2022
Source: ECCO'22
Authors: Vermeire, S.(1);Feagan, B.(2,3);Peyrin-Biroulet, L.(4);Oortwijn, A.(5);Faes, M.(6);de Haas, A.(5);Rogler, G.(7);
Created: Friday, 11 February 2022, 3:56 PM
P517: The effects and adherence of Asacol® comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: Prospective multicentre randomised study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-K. Park1*, C.S. Eun2, G.S. Seo3, J. Lim4, T.O. Kim5, D.I. Park1

Created: Thursday, 21 February 2019, 9:14 AM
P517: Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ramos Lopez, L.(1);Ramos-Díaz, R.(2);Alonso-Abreu, I.(1);Mourani-Padron, I.(2);Carrillo-Palau, M.(1);Reygosa, M.C.(1)*;Medina-Chico, S.(1);Gutierrez-Nicolas, F.(3);Nazco-Casariego, G.J.(3);Hernandez-Guerra, M.(4);
Created: Friday, 14 July 2023, 11:05 AM
P518 Ulcerative colitis drug development success rates are higher than the industry average
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Georgiev1, F. Hussain1, M. Copeman2, M. Delegge1, M.B. Gallagher1, T. Stewart1, W. Reinisch3

Created: Thursday, 30 January 2020, 10:12 AM
P518: Cardiovascular Risk Factors in Adolescents with inflammatory bowel disease: A Cross-sectional Population-Based Study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Ghersin*1, L. H. Katz2,3, S. Daher4, R. Shamir3,5, A. Assa3,5

Created: Friday, 22 February 2019, 9:41 AM
P518: Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID.
Year: 2021
Source: ECCO'21 Virtual
Authors: Edwards, D.(1);Ibrahim, M.(2);Cooney, R.(2);Boulton, R.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P518: Partial enteral nutrition use for Crohn’s disease management: a systematic review
Year: 2022
Source: ECCO'22
Authors: Jatkowska, A.(1);White, B.(1);Gkikas, K.(1);Seenan, J.P.(2);MacDonald, J.(2);Gerasimidis, K.(1);
Created: Friday, 11 February 2022, 3:56 PM